A randomized, open label, active-controlled, parallel-group, multicenter, Phase III study to evaluate efficacy, safety, and tolerability of Revefenacin inhalationsolution 175 mcg versus Tiotropium dry powder for inhalation 18 mcg in subjects with Chronic Obstructive Pulmonary Disease (COPD)

This will be a multicenter, randomized study including 362 subjects with COPD. Subjects will receive study drug for 12 weeks. Study drug (Revefenacin inhalation solution 175 mcg OD)will be administered using a standard jet nebulizer and compressor via a mouthpiece. Comparator drug (Tiotropium 18mcg OD) will be administered via dry powder inhaler. Subjects will berandomly assigned in a 1:1 ratio, as per randomization code. Subjects will have approximately 6 visits (encompassing a screening period of up to 15 days and a treatment period of 12weeks). Adverse events, concomitant medication use, and rescue medication use since the previous visit will be reviewed at each visit.